VERACYTE, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for VERACYTE, INC. (VCYT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are VCYT insiders buying or selling?
In the last 12 months, VERACYTE, INC. insiders reported 0 open-market purchases ($0) and 33 sales ($21.0M) — net selling of $21.0M. Since June 2018, Trabud has recorded 201 Form 4 filings for VCYT: 2 buys ($1.1M) and 199 sells ($275.2M).
Source: SEC EDGAR Form 4
What stands out
- No VERACYTE, INC. insider made an open-market purchase in the last 12 months; the 33 reported open-market sales totaled $21.0M.
Key Statistics (June 2018 – Sep 22, 2026)
Total Form 4 filings
201
SEC EDGAR
Insider filers
21
Insider buys (2)
$1.1M
Insider sells (199)
$275.2M
Insider sentiment
Net sellingNet insider flow of $274.1M in net selling since June 2018, and $21.0M in net selling over the last 12 months.
Recent VCYT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | John Leite | Global Chief Commercial Off | Sale | 4.0K | $40.00 | $160.6K | SEC ↗ |
| Sep 16, 2026 | Jens Holstein | Director | Sale | 5.0K | $40.95 | $204.7K | SEC ↗ |
| Sep 4, 2026 | Phillip G. Febbo | Chief Scientific & Med Officer | Sale | 13.1K | $43.05 | $564.4K | SEC ↗ |
| Sep 4, 2026 | Rebecca Chambers | Chief Financial Officer | Sale | 3.7K | $43.10 | $157.4K | SEC ↗ |
| Sep 4, 2026 | Annie Mcguire | EVP, General Counsel | Sale | 3.3K | $43.09 | $140.2K | SEC ↗ |
| Sep 3, 2026 | Muna Bhanji | Director | Sale | 1.9K | $42.97 | $80.1K | SEC ↗ |
| Jun 22, 2026 | Karin Eastham | Director | Sale | 3.7K | $52.89 | $197.2K | SEC ↗ |
| Jun 5, 2026 | Annie Mcguire | EVP, General Counsel | Sale | 3.2K | $49.76 | $158.0K | SEC ↗ |
| Jun 5, 2026 | Rebecca Chambers | Chief Financial Officer | Sale | 3.6K | $49.73 | $177.1K | SEC ↗ |
| Jun 5, 2026 | Marc Stapley | Chief Executive Officer | Sale | 138.1K | $50.12 | $6.9M | SEC ↗ |
| Jun 5, 2026 | John Leite | Global Chief Commercial Off | Sale | 14.0K | $50.07 | $699.7K | SEC ↗ |
| May 27, 2026 | Jonathan Wygant | VP, Chief Accounting Officer | Sale | 24.0K | $45.40 | $1.1M | SEC ↗ |
| May 22, 2026 | Robert S Epstein | Director | Sale | 10.0K | $44.01 | $440.1K | SEC ↗ |
| May 8, 2026 | Annie Mcguire | SVP, General Counsel | Sale | 10.2K | $39.03 | $398.2K | SEC ↗ |
| Mar 6, 2026 | Rebecca Chambers | Chief Financial Officer | Sale | 18.3K | $36.14 | $662.9K | SEC ↗ |
| Mar 6, 2026 | Marc Stapley | Chief Executive Officer | Sale | 45.5K | $35.97 | $1.6M | SEC ↗ |
| Mar 6, 2026 | John Leite | Chief Commercial Officer-CLIA | Sale | 5.3K | $35.19 | $185.1K | SEC ↗ |
| Mar 6, 2026 | Annie Mcguire | SVP, General Counsel | Sale | 6.7K | $35.55 | $236.7K | SEC ↗ |
| Mar 4, 2026 | Phillip G. Febbo | Chief Scientific & Med Officer | Sale | 13.4K | $36.16 | $485.4K | SEC ↗ |
| Dec 17, 2025 | Annie Mcguire | SVP, General Counsel | Sale | 10.7K | $43.13 | $463.2K | SEC ↗ |
| Dec 8, 2025 | Karin Eastham | Director | Sale | 20.0K | $45.45 | $908.9K | SEC ↗ |
| Dec 5, 2025 | Annie Mcguire | SVP, General Counsel | Sale | 1.4K | $47.30 | $67.3K | SEC ↗ |
| Dec 5, 2025 | Rebecca Chambers | Chief Financial Officer | Sale | 13.3K | $46.84 | $622.0K | SEC ↗ |
| Dec 5, 2025 | Marc Stapley | Chief Executive Officer | Sale | 7.7K | $47.09 | $361.1K | SEC ↗ |
| Dec 5, 2025 | John Leite | Chief Commercial Officer-CLIA | Sale | 1.3K | $47.51 | $60.7K | SEC ↗ |
Showing the 25 most recent of 201 Form 4 filings for VERACYTE, INC..
Most active VCYT insiders
- Bonnie H Anderson41 filings
- Giulia C Kennedy25 filings
- Evan/ FA Jones22 filings
- Karin Eastham18 filings
- John Leite12 filings
Ask anything about VCYT insider activity
Use Trabud's AI agent to query VERACYTE, INC.'s Form 4 history in plain English — "Show me VCYT CEO purchases this year" or compare it against any other ticker.
Open the AI agentVCYT insider trading FAQ
Are VERACYTE, INC. insiders buying or selling?
In the last 12 months, VERACYTE, INC. insiders reported 0 open-market purchases ($0) and 33 sales ($21.0M) — net selling of $21.0M. Since June 2018, Trabud has recorded 201 Form 4 filings for VCYT: 2 buys ($1.1M) and 199 sells ($275.2M). Over the full record that is net selling of $274.1M.
How many insiders trade VCYT stock?
21 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for VERACYTE, INC.. The most recent filing was accepted on Sep 22, 2026.
Where does Trabud get VCYT insider trading data?
All VCYT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.